St. John Hospital Enrolls PAD Patient in Avinger's CONNECT II Clinical Trial

http://www.stjohnprovidence.org/newsroom Detroit— St. John Hospital and Medical Center announces its participation in CONNECT II, a global clinical trial conditionally approved by the FDA that gives physicians access to a sophisticated new imaging technology tool to fight peripheral arterial disease. The technology, called Ocelot, helps to eliminate the need for bypass surgeries and/or amputations in patients with the disease. Each year, nearly 200,000 amputations occur as a result of PAD and many of them can be avoided. CONNECT II is a prospective, multi-center, non-randomized global clinical study that will evaluate Ocelot, the first-ever interventional device that allows physicians that treat peripheral artery disease to drill through totally blocked arteries in the legs while using an integrated camera to see from inside the artery.